Tesamorelin vs 5-Amino-1MQ
Both Tesamorelin and 5-Amino-1MQ are used for fat-loss. Here's how their evidence, dosing, and regulatory status actually compare.
Tesamorelin
Evidence ATesamorelin (Egrifta)
An FDA-approved GHRH analog that stimulates natural growth hormone production. Clinically proven to reduce visceral adipose tissue and increasingly used off-label for body recomposition.
View full Tesamorelin profile →5-Amino-1MQ
Evidence C+5-Amino-1-Methylquinolinium
A small-molecule NNMT inhibitor that has produced fat loss and improved muscle stem-cell function in obese rodents. No human RCTs yet.
View full 5-Amino-1MQ profile →Side-by-Side
| Attribute | Tesamorelin | 5-Amino-1MQ |
|---|---|---|
| Evidence Grade | A | C+ |
| FDA Status | FDA-approved for HIV-associated lipodystrophy | Not FDA-approved — small-molecule research compound (NNMT inhibitor) |
| Typical Dose | 2 mg daily (subcutaneous) | 50–150 mg orally daily (research-only) |
| Clinics Indexed | 178 | 31 |
| Categories | growth-hormone, fat-loss | fat-loss, longevity |
Key reported benefits — Tesamorelin
- ✓Visceral fat reduction
- ✓Natural GH stimulation
- ✓Cognitive benefit
- ✓Lean mass
Key reported benefits — 5-Amino-1MQ
- ✓NNMT inhibition
- ✓Fat-mass reduction (preclinical)
- ✓Muscle stem-cell support
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.